ID: ALA447959

Max Phase: Preclinical

Molecular Formula: C17H22Cl2N2O2S

Molecular Weight: 352.89

Molecule Type: Small molecule

Representations

Canonical SMILES:  CSC[C@@H]1CO[C@@](CCc2ccc(Cl)cc2)(Cn2ccnc2)O1.Cl

Standard InChI:  InChI=1S/C17H21ClN2O2S.ClH/c1-23-11-16-10-21-17(22-16,12-20-9-8-19-13-20)7-6-14-2-4-15(18)5-3-14;/h2-5,8-9,13,16H,6-7,10-12H2,1H3;1H/t16-,17+;/m0./s1

Standard InChI Key:  PXJCYQITNKBFPY-MCJVGQIASA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 352.89

Molecular Weight (Monoisotopic): 352.1012

AlogP: 3.64

#Rotatable Bonds: 7

Polar Surface Area: 36.28

Molecular Species: NEUTRAL

HBA: 5

HBD: 0

#RO5 Violations: 0

HBA (Lipinski): 4

HBD (Lipinski): 0

#RO5 Violations (Lipinski): 0

CX Acidic pKa:

CX Basic pKa: 6.43

CX LogP: 4.06

CX LogD: 4.03

Aromatic Rings: 2

Heavy Atoms: 23

QED Weighted: 0.76

Np Likeness Score: -0.47

References

1. Vlahakis JZ, Kinobe RT, Nakatsu K, Szarek WA, Crandall IE..  (2006)  Anti-Plasmodium activity of imidazole-dioxolane compounds.,  16  (9): [PMID:16495054] [10.1016/j.bmcl.2006.01.122]

2. Vlahakis JZ, Hum M, Rahman MN, Jia Z, Nakatsu K, Szarek WA..  (2009)  Synthesis and evaluation of imidazole-dioxolane compounds as selective heme oxygenase inhibitors: effect of substituents at the 4-position of the dioxolane ring.,  17  (6): [PMID:19268600] [10.1016/j.bmc.2009.01.078]

Source

Source(1):

• Scientific Literature